이재련 교수
#비뇨기암#전이성비뇨기종양
|
학력
2005 .03 ~ 2007 .08울산대학교 의학 박사
2001 .09 ~ 2005 .02영남대학교 의학 석사
1987 .03 ~ 1993 .02영남대학교 의학 학사
2001 .09 ~ 2005 .02영남대학교 의학 석사
1987 .03 ~ 1993 .02영남대학교 의학 학사
경력
2017 .04 ~ 현재울산의대 서울아산병원 종양내과 교수
2011 .04 ~ 2017 .03울산의대 서울아산병원 종양내과 부교수
2009 .04 ~ 2010 .06University of Wisconsin Carbone Cancer Center 비뇨기암 및 1상임상시험센터
2004 .09 ~ 2010 .02울산의대 서울아산병원 종양내과 조교수
2003 .03 ~ 2004 .08영남대학교 의과대학 혈액종양내과 전임강사
2002 .03 ~ 2003 .02서울아산병원 임상강사
2001 .05 ~ 2002 .02영남대학교 의과대학 부속병원 전임의
1994 .03 ~ 1998 .02영남대학교 의과대학 부속병원 레지던트
1993 .03 ~ 1994 .02영남대학교 의과대학 부속병원 인턴
논문
Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-line Treatment for Patients with Recurrent or Metastatic Biliary Tract Cancer.
Pazopanib for the Treatment of Non-Clear Cell Renal Cell Carcinoma: A Single-Arm, Open-Label, Multicenter, Phase II Study.
Phase II Study of Dovitinib in Patients with Castration-Resistant Prostate Cancer (KCSG-GU11-05).
Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial.
A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma.
Characterizing the outcomes of metastatic papillary renal cell carcinoma.
Clinical outcome of high-dose bolus intravenous interleukin-2 with a modified administration schedule for Asian patients with metastatic renal cell carcinoma.
Comparison of outcomes between trimodal therapy and radical cystectomy in muscle-invasive bladder cancer: a propensity score matching analysis.
Development of Response Classifier for Vascular Endothelial Growth Factor Receptor (VEGFR)-Tyrosine Kinase Inhibitor (TKI) in Metastatic Renal Cell Carcinoma.
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study.
Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen
Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testing.
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial.
Second-line Chemotherapy in Older Patients With Metastatic Urothelial Carcinoma: Pooled Analysis of 10 Second-line Studies.
Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Use of a High-Throughput Genotyping Platform (OncoMap) for RAS Mutational Analysis to Predict Cetuximab Efficacy in Patients with Metastatic Colorectal Cancer.
A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma.
Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations.
Donor-Derived Natural Killer Cell Infusion after Human Leukocyte Antigen?Haploidentical Hematopoietic Cell Transplantation in Patients with Refractory Acute Leukemia
Pazopanib for the Treatment of Non-Clear Cell Renal Cell Carcinoma: A Single-Arm, Open-Label, Multicenter, Phase II Study.
Phase II Study of Dovitinib in Patients with Castration-Resistant Prostate Cancer (KCSG-GU11-05).
Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial.
A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma.
Characterizing the outcomes of metastatic papillary renal cell carcinoma.
Clinical outcome of high-dose bolus intravenous interleukin-2 with a modified administration schedule for Asian patients with metastatic renal cell carcinoma.
Comparison of outcomes between trimodal therapy and radical cystectomy in muscle-invasive bladder cancer: a propensity score matching analysis.
Development of Response Classifier for Vascular Endothelial Growth Factor Receptor (VEGFR)-Tyrosine Kinase Inhibitor (TKI) in Metastatic Renal Cell Carcinoma.
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study.
Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen
Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testing.
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial.
Second-line Chemotherapy in Older Patients With Metastatic Urothelial Carcinoma: Pooled Analysis of 10 Second-line Studies.
Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Use of a High-Throughput Genotyping Platform (OncoMap) for RAS Mutational Analysis to Predict Cetuximab Efficacy in Patients with Metastatic Colorectal Cancer.
A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma.
Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations.
Donor-Derived Natural Killer Cell Infusion after Human Leukocyte Antigen?Haploidentical Hematopoietic Cell Transplantation in Patients with Refractory Acute Leukemia
저서
암에 대한 모든 것 (가림건강신서 54)
위장관 간질종양 -환자를 위한 치료지침서
위장관 간질종양 -환자를 위한 치료지침서
보도자료
“방광암서 PD-L1, 바이오마커로 가치 불충분”
http://www.yakup.com/news/index.html?mode=view&cat=12&nid=222480
"키트루다-엑시티닙 병용, 신장암 新치료 패러다임 가능성"
http://www.dailymedi.com/detail.php?number=851006&thread=22r03
http://www.yakup.com/news/index.html?mode=view&cat=12&nid=222480
"키트루다-엑시티닙 병용, 신장암 新치료 패러다임 가능성"
http://www.dailymedi.com/detail.php?number=851006&thread=22r03
포스팅
Epithelial-mesenchymal transition as a mechanism of acquired tyrosine kinase inhibitor resistance in clear cell renal cell carcinoma
Temsirolimus versus VEGFR TKIs for Patients with Metastatic Non-clear-Cell Renal Cell Carcinoma
Efficacy of Chemotherapy in Patients with Pancreatic Acinar Cell Carcinoma
Pazopanib versus sunitinib as first-line treatment in metastatic renal cell carcinoma with poor risk features
RandomizEd phase II trial of Sunitinib four-week on and two-week off vs.Two-week On and one-week off in metastatic clear cell type REnal cell carcinoma: RESTORE trial (NCT00570882)
Analysis of preoperative variables to identify patients who would likely benefit from upfront cytoreductive nephrectomy
Activity of gemcitabine-oxaliplatin (GemOx) plus prednisolone in patients with castration-resistant prostate cancer (CRPC) for whom docetaxel-based chemotherapy failed
Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI) is Active in Patients with Metastatic Renal Cell Carcinoma (mRCC) with Poor Risk Features
Comparative Efficacy of Sunitinib versus Sorafenib as First-line Treatment for Patients with Metastatic Renal Cell Carcinoma
A prospective multicenter phase II study of sunitinib in patients with advanced aggressive fibromatosis (desmoid tumor)
Primary urethral cancer: A retrospective analysis of 27 patients at a single institute
Does the primary lesion have to be regarded as a target lesion when evaluating response in metastatic renal cell carcinoma (mRCC) treated with sunitinib?
Role of molecular markers in nephrectomyspecimenas prognosticators for patients with metastatic renal cell carcinomain the era of targeted therapy
Temsirolimus versus VEGFR TKIs for Patients with Metastatic Non-clear-Cell Renal Cell Carcinoma
Efficacy of Chemotherapy in Patients with Pancreatic Acinar Cell Carcinoma
Pazopanib versus sunitinib as first-line treatment in metastatic renal cell carcinoma with poor risk features
RandomizEd phase II trial of Sunitinib four-week on and two-week off vs.Two-week On and one-week off in metastatic clear cell type REnal cell carcinoma: RESTORE trial (NCT00570882)
Analysis of preoperative variables to identify patients who would likely benefit from upfront cytoreductive nephrectomy
Activity of gemcitabine-oxaliplatin (GemOx) plus prednisolone in patients with castration-resistant prostate cancer (CRPC) for whom docetaxel-based chemotherapy failed
Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI) is Active in Patients with Metastatic Renal Cell Carcinoma (mRCC) with Poor Risk Features
Comparative Efficacy of Sunitinib versus Sorafenib as First-line Treatment for Patients with Metastatic Renal Cell Carcinoma
A prospective multicenter phase II study of sunitinib in patients with advanced aggressive fibromatosis (desmoid tumor)
Primary urethral cancer: A retrospective analysis of 27 patients at a single institute
Does the primary lesion have to be regarded as a target lesion when evaluating response in metastatic renal cell carcinoma (mRCC) treated with sunitinib?
Role of molecular markers in nephrectomyspecimenas prognosticators for patients with metastatic renal cell carcinomain the era of targeted therapy
영상자료
영상자료 내용이 없습니다.
발표자료
Clinical significance of post-chemotherapy PSA surge syndrome in patient with HRPC treated with docetaxel-based chemotherapy
Role of androgen deprovation treatment in patients with castration-resistant prostate cancer receiving docetaxel chemotherapy
Surgical resection after imatinib treatment in patients with metastatic or unresectable gastrointestinal stromal tumors
Salvage Chemotherapy with Irinotecan, 5-fluorouracil and Leucovorin in Patients with Advanced Gastric Cancer
No Relationship between C-kit Mutation and Response to Imatinib in Korean Patients with Metastatic Gastrointestinal Stromal Tumor
Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors of the Stomach:Report of Three Cases
Improved survival of metastatic GIST patients in post-imatinib era compared to those in pre-imatinib era
Cetuximab plus FOLFIRI for irinotecan-refractory metastatic colorectal cancer: A retrospective study
Phase I/II Study of Combination Chemotherapy with S-1 and Cisplatin in Patients with Previously Untreated Metastatic or Recurrent Advanced Gastric Cancer (AGC)
Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin in patients with advanced gastric cancer
No relationship between c-kit mutation and response to imatinib in Korean patients with metastatic gastrointestinal stromal tumor
Efficacy and safery study of epirubicn and etoposide combination chemotherapy in advanced hepatocellular carcinoma
Phase I/II study of combination chemotherapy with S-1 and cisplatin in patients with previously untreated metastatic or recurrent gastric cancer
Efficacy and Safety Study of Epirubicin and Etoposide Combination Chemotherapy in Advanced Hepatocellular Carcinoma
Clinical Outcome in Gastrointestinal Stromal Tumor Patients who Interrupted Imatinib after Achieving Stable Disease or Better Response
Role of androgen deprovation treatment in patients with castration-resistant prostate cancer receiving docetaxel chemotherapy
Surgical resection after imatinib treatment in patients with metastatic or unresectable gastrointestinal stromal tumors
Salvage Chemotherapy with Irinotecan, 5-fluorouracil and Leucovorin in Patients with Advanced Gastric Cancer
No Relationship between C-kit Mutation and Response to Imatinib in Korean Patients with Metastatic Gastrointestinal Stromal Tumor
Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors of the Stomach:Report of Three Cases
Improved survival of metastatic GIST patients in post-imatinib era compared to those in pre-imatinib era
Cetuximab plus FOLFIRI for irinotecan-refractory metastatic colorectal cancer: A retrospective study
Phase I/II Study of Combination Chemotherapy with S-1 and Cisplatin in Patients with Previously Untreated Metastatic or Recurrent Advanced Gastric Cancer (AGC)
Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin in patients with advanced gastric cancer
No relationship between c-kit mutation and response to imatinib in Korean patients with metastatic gastrointestinal stromal tumor
Efficacy and safery study of epirubicn and etoposide combination chemotherapy in advanced hepatocellular carcinoma
Phase I/II study of combination chemotherapy with S-1 and cisplatin in patients with previously untreated metastatic or recurrent gastric cancer
Efficacy and Safety Study of Epirubicin and Etoposide Combination Chemotherapy in Advanced Hepatocellular Carcinoma
Clinical Outcome in Gastrointestinal Stromal Tumor Patients who Interrupted Imatinib after Achieving Stable Disease or Better Response